Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies.

[1]  Tetanus vaccines: WHO position paper, February 2017 - Recommendations. , 2018, Vaccine.

[2]  G. Giardino,et al.  Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab , 2017, International reviews of immunology.

[3]  Natasha S. Crowcroft,et al.  Diphtheria in the Postepidemic Period, Europe, 2000–2009 , 2012, Emerging infectious diseases.

[4]  A. Tierens,et al.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. , 2011, Blood.

[5]  N. Sarper,et al.  Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re‐vaccination , 2009, Pediatric blood & cancer.

[6]  J. Friedberg,et al.  Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma , 2008, Cancer investigation.

[7]  U. Göbel,et al.  Diphtheria (D) and Tetanus (T) Antibody Values in Children with Acute Lymphoblastic Leukaemia (ALL) after Treatment According to Co-ALL 05/92 , 2007, Klinische Padiatrie.

[8]  J. Abrahamsson,et al.  Intensive Treatment for Childhood Acute Lymphoblastic Leukemia Reduces Immune Responses to Diphtheria, Tetanus, and Haemophilus influenzae Type b , 2004, Journal of pediatric hematology/oncology.

[9]  Ả. Svensson,et al.  Immunity to tetanus, diphtheria and poliomyelitis in the adult population of Sweden in 1991. , 1998, International journal of epidemiology.

[10]  P. Ljungman,et al.  Tetanus immunity in patients with hematological malignancies , 1998, Supportive Care in Cancer.

[11]  World Health Organization.  Diphtheria vaccine: WHO position paper, August 2017 - Recommendations. , 2018, Vaccine.

[12]  Polio vaccines: WHO position paper – March, 2016. , 2016, Releve epidemiologique hebdomadaire.